INTRODUCTION
============

Preterm premature rupture of membranes (PPROM) occurs in approximately 3% of all pregnancies, accounting for nearly 1/3 of all preterm births \[[@B1]--[@B5]\] . Moreover, PPROM is a contributor to perinatal morbidity and mortality---primarily due to its association with delivery remote from term, chorioamnionitis, placental abruption, and umbilical cord compression or prolapse \[[@B1], [@B2]\]

Management of women with HIV infection who develop PPROM poses an obstetric dilemma. Limited data are available to direct optimal management of HIV-positive women who develop PPROM. Previous investigations have demonstrated that in term pregnancies complicated by maternal HIV infection, duration of membrane rupture \> 4 hours increases the risk of intrapartum vertical transmission \[[@B12]--[@B17]\]. By extrapolation of this data, some authors suggest that women with HIV who undergo PPROM should not be managed conservatively \[[@B1], [@B12]--[@B14]\]. However, in instances near the limits of viability, conservative management of PPROM may be justified because of the extremely high risk of mortality and chronic morbidity when immediate delivery is prompted \[[@B1]\]. We and others \[[@B1]\] have been unable to identify any published manuscripts to date reporting on conservative management of PPROM in the setting of HIV (Medline search 1 January 1966--1 September 2005: search terms: preterm premature rupture of membranes, human immunodeficiency virus infection, acquired immunodeficiency syndrome). Given an absolute lack of published reports, we sought to provide an initial report on the management and outcomes of a series of HIV-infected women whose pregnancies were complicated by preterm premature rupture of membranes (PPROM).

MATERIALS AND METHODS
=====================

*Discussion of management options*

In each instance, a thorough and complete review of the relative risks of prematurity and PPROM remote from term and potential for vertical transmission with prolonged rupture of the membranes was reviewed with the patient, and documented in the patient chart. These discussions involved obstetrician/gynecologists, maternal-fetal medicine specialists, neonatologists, and/or infectious disease specialists, with language interpreters as indicated.

*Study population*

At Hennepin County Medical Center (HCMC), the HIV-infected women were identified through the HCMC HIV database encompassing the interval from 1990 to 2004, and the electronic medical records (EMRs) system was reviewed to identify whether they had been seen through the obstetrics and gynecology clinics, high-risk obstetrics clinics, or on labor and delivery. For those with identified encounters, exhaustive review of both the EMR and patient chart was undertaken to ascertain whether a pregnancy had occurred, and whether the pregnancy had been complicated by PPROM remote from term. At The University of Alabama at Birmingham (UAB), an electronic obstetric database (OBAR) of women who obtained their prenatal care and delivered at UAB from 1980 to 2004 was searched. Women with HIV having undergone PROM were identified and for those women in whom latency was greater than 24 hours, an exhaustive chart review was performed.

*Definitions*

PPROM remote from term was defined as preterm, premature rupture of the membranes prior to 32-week gestation confirmed by ferning, pooling, or indigo-carmine amnioinfusion; dating was by previously published American College of Obstetricians and Gynecologist (ACOG) criteria and employed last menstrual period with fetal biometry by ultrasonographic determination \[[@B22]\]. Maternal HIV-positive status was defined as documentation of HIV-1 or HIV-2 seroconversion, confirmed by Western blot analysis. AIDS was defined as an absolute CD4+, CD3+ lymphocyte count less than 200 ×10^6^ cells/L. Infants were considered infected if they were HIV-seropositive, confirmed by Western blot at \> 18 months of age, had two or more positive PCR tests or viral cultures at any age, had an AIDS-defining illness, or if they died with an HIV-related condition.

*Data extraction*

Once a pregnancy was identified as having been dually complicated by HIV-positive maternal status and PROM remote from term, data was uniformly extracted from the patients chart with respect to maternal characteristics (age, ethnicity, parity, year of HIV-positive diagnosis, past medical history, polysubstance abuse history, and infectious comorbidities), prenatal care (gestational age and dating criteria, gestational age at initiation of prenatal care, gestational age at initiation of HAART/therapy, number of prenatal visits), HIV characteristics (genotype, AIDS, infectious comorbidities \[GBS, *trichomonas, gonorrhea, Chlamydia*, PPD, Hepatitis A, B, or C\]), PPROM characteristics (means of confirmation, most recent viral load and CD4 count prior to PPROM, antiviral therapy at PPROM, gestational age at delivery, latency interval, indication for delivery, clinical or histologic evidence of chorioamnionitis), use of antiviral and antimicrobial therapy (HAART/intrapartum AZT, duration of use, utilization of antibiotics for the prolongation of latency), maternal peripartum complications (sepsis, chorioamnionitis, endometritis), and fetal and infant characteristics (administration of steroids for the promotion of fetal lung maturity, infant sex, birth weight, APGARS, cord gasses, NICU admission and duration of NICU stay, neonatal sepsis, RDS, IVH, necrotizing enterocolitis, vertical transmission, other complications or medical morbidities).

*IRB approval*

At HCMC, the HIV database for women with HIV is supported by Infectious Disease HIV Clinic with IRB approval. As this represented a case series, no further IRB approval was deemed necessary. At UAB, expedited IRB approval was obtained for chart review and data extraction.

RESULTS
=======

*Patient characteristics ([Table 1](#T1){ref-type="table"})*

Over the indicated study intervals at HCMC and UAB, Birmingham, we identified 291 pregnancies having occurred in the cohort of HIV-positive women. Of these pregnancies, 7 (2.4%) developed PPROM with subsequent delivery from 25-to 32-week gestation. With the exception of one patient (patient 1), all women received prenatal care in their first or early midtrimester. For those who received adequate prenatal care, medical comorbidities reported reflect those found in the at-large HCMC and UAB populations.

*HIV and infectious morbidity ([Table 2](#T2){ref-type="table"})*

With the exception of two patients (patients 2 and 6), all women were aware of their diagnosis of HIV prior to the pregnancy. Note that the diagnosis of HIV seroconversion (for patient 1) occurred in a prior pregnancy, but treatment was never initiated secondary to failed followup; this was in spite of multiple attempts to encourage compliance with care.

Each of the patients who received prenatal care at HCMC was initiated on HAART in the early midtrimester; two of these patients continued a modification of their prepregnancy therapy ([Table 2](#T2){ref-type="table"}). At UAB, both pregnancies occurred (1993) prior to the use of HAART in pregnancy. One woman (patient 6) was part of the PACTG 076 trial and was randomized to placebo. The second patient was receiving AZT prepregnancy and continued this regimen antepartum.

All patients were screened for viral and bacterial infectious comorbidities on initial presentation; all were rescreened on admission. None were Hepatitis B surface antigen-positive, one was Hepatitis C positive (patient 7); one (patient 3) had been previously exposed to Hepatitis A but was without active disease. Three of the 7 patients had *Trichomonas vaginalis* detected and treated, and one woman (patient 1) was positive and treated for *Trichomonas, C trachomatis*, and *N gonorrhea* at the time of admission. All women were RPR nonreactive on admission (data not shown). Two women (patients 3 and 7) had a history of tuberculosis, and had previously received therapy accordingly.

*PPROM and delivery characteristics ([Table 3](#T3){ref-type="table"})*

Each patient in our series was distinct from the others with respect to gestational age at the time of PPROM; however, the overall profile typifies that seen among HIV-negative women with PPROM. In one instance (patient 2), PPROM occurred prior to viability and extensive counseling regarding the risks of oligohydramnios and prolonged ruptured membranes was undertaken. The patient elected to pursue expectant management.

With respect to viral load at the time of PPROM, one woman (patient 1) was hospitalized for preterm labor when rupture of membranes occurred. With respect to patients 2 and 5, noncompliance with outpatient HAART was problematic prior to PPROM. However, with inpatient management (patient 5) and frequent outpatient visits (patient 2), compliance improved and the viral load declined accordingly ([Table 3](#T3){ref-type="table"}). As per protocol standard at the time of presentation, viral loads were not obtained in the women that delivered at UAB.

All patients with ongoing pregnancies at HCMC received intravenous AZT for a maximum of 48 hours following membrane rupture, with repeat administration of therapy proximal to delivery. During the same interval, HAART was utilized as per their antepartum regimen ([Table 3](#T3){ref-type="table"}). The single exception to optimal utilization of intrapartum AZT use was patient 3, as she had experienced a prior episode of neutropenic sepsis with ARDS. At UAB, intrapartum AZT was not administered to one woman (patient 6) as per study (PACTG 076) protocol following randomization to placebo. In another patient, intravenous AZT was administered for 60 hours during her prolonged latent phase (from the time of admission to the time of delivery).

The mean latency in this cohort was 17.1 days with a median of 5 days; one woman (patient 2) had a latency of 92 days. Indications for delivery typified that of pregnancies complicated by PPROM, and mode of delivery was determined by obstetrical indications ([Table 3](#T3){ref-type="table"}).

*Maternal complications ([Table 3](#T3){ref-type="table"})*

Clinical or histologic evidence of chorioamnionitis was prevalent; endometritis ensued in four cases. There was one instance of maternal sepsis with positive blood cultures for *Peptostreptococcus*. Otherwise, the duration of postdelivery hospitalization mirrored that of the general obstetric population at the respective institutions.

*Infant sequelae and complications ([Table 4](#T4){ref-type="table"})*

Neonatal outcomes of the pregnancies in our series are shown in [Table 4](#T4){ref-type="table"}. Vertical HIV transmission was noted in 2 of the possible 6 cases (33%). In the two instances of vertical transmission, one woman and infant pair received no antiretroviral therapy as per study (PACTG 076) protocol. In the second instance, AZT was the only antiretroviral employed and viral loads were not used to guide delivery practice. All infants (except for patient 6 (PACTG 076 protocol)) received antiretroviral therapy in the neonatal period as per standard of care. Of the cases without vertical transmission in our series, all women received HAART at the time of PPROM with cesarean delivery for those with a viral load \> 1000 copies/mL.

COMMENTS
========

In our series, there were no instances of vertical transmission in women with PPROM who were receiving multidrug therapy or HAART despite prolonged intervals of rupture of membranes. The only two cases of vertical transmission observed were in one woman who did not receive antepartum or intrapartum antiretroviral therapy, and in another who received only AZT in the antepartum period. Our observations suggest that in the era of HAART, one might consider whether or not immediate delivery should be undertaken in pregnancies complicated by PPROM at an early gestational age. Alternatively, in pregnancies that may lend themselves to expectant management, such a strategy should be entertained.

In pregnancies complicated by maternal HIV infection, duration of rupture of membranes \> 4 hours, in term pregnancies appear to increase the risk of intrapartum vertical transmission \[[@B12]--[@B17]\]. In one study \[[@B19]\], prolonged rupture of membranes in term (\> 37 weeks) relative to preterm (\< 37 weeks) was assessed. The authors found a 3.8-fold RR (95% CI 1.9, 7.8) increase in intrapartum HIV transmission when comparing preterm to term infants whose membranes had been ruptured \> 4 hours. These authors attempted to delineate whether vertical transmission occurred in the intrauterine or intrapartum period and came to the conclusion that "preterm infants are at increased risk of acquiring infection at the time of delivery," see \[[@B19]\]. However, transmission risk was not stratified by use of antiretroviral therapy, gestational age, nor mode of delivery \[[@B19]\]. As with this study, other studies \[[@B12]--[@B17]\] exploring the relationship of duration of membrane rupture and perinatal HIV transmission have failed to account for the use of HAART and viral load at the time of delivery.

One recent analysis \[[@B23]\] investigated the risk of perinatal HIV transmission in women on combination antiretroviral therapy with viral loads \< 1000 copies/mL and membrane rupture \> 4 hours. Duration of membrane rupture was not a risk factor for vertical transmission. Interestingly, monotherapy (OR 6.3, CI 2.4−16.6) or lack of antiretroviral therapy (OR 17.4 CI 6.7−45.5) and viral load \> 1000 copies/mL (OR 9.9, CI 1.2−84.5) were independently associated with neonatal infection. Our case series suggests that this relationship between combination antiretroviral therapy and reduction in the rate of vertical transmission may apply to pregnancies complicated by prolonged premature preterm rupture of membranes and HIV.

We recognize that the primary limitation of this study is its limited sample size and its heterogeneous population. Our series does not claim to provide any statistical risk assessment for counseling patients on the relative merits or risks of transmission in the setting of PPROM remote from term. Rather, it is our hope that this novel series will provide an impetus to further reports and larger multi-institutional investigations to address this important clinical issue.

CONDENSATION
============

We report a novel case series describing management and outcomes in human immunodeficiency virus-infected women who developed preterm premature rupture of membranes remote from term.

###### 

Patient characteristics on admission. PNC: prenatal care; ARDS: adult respiratory distress syndrome; AZT: zidovudine; AIDS: acquired immunodeficiency syndrome; N/A: data not available.

  ---------------------- ---------------- --------------------- ------------------ ----------------- ----------------------- ----------------- ---------------------------- ------------- ------
  Patient                Age (years)      Parity                Ethnicity          Gestational age   Medical comorbidities   Substance abuse   HIV diagnosis in pregnancy   Duration of   AIDS
  at initiation of       HIV infection                                                                                                                                                    
  prenatal care          (years)                                                                                                                                                          
                                                                                                                                                                                          
  1                      24               2103                  African            No PNC prior      Polysubstance           Yes               No                           1             No
  American               to admission     abuse                 (cocaine)                                                                                                                 
                                                                                                                                                                                          
  2                      25               1001                  Caucasian          13 0/7            Polysubstance           Yes               Yes                          0             No
  abuse                  (cocaine)                                                                                                                                                        
                                                                                                                                                                                          
  3                      30               5013                  African            15 3/7            History of              No                No                           3             No
  neutropenic sepsis                                                                                                                                                                      
  with ARDS                                                                                                                                                                               
  secondary to AZT                                                                                                                                                                        
  therapy                                                                                                                                                                                 
                                                                                                                                                                                          
  4                      30               1001                  Latino             5 2/7             Chronic pain            No                No                           11            No
  Anxiety                                                                                                                                                                                 
  Appendicitis                                                                                                                                                                            
  (21-week gestation)                                                                                                                                                                     
                                                                                                                                                                                          
  5                      33               2012                  Native             7 0/7             Remote history of       Yes               No                           7             No
  American               pyelonephritis   (marijuana alcohol)                                                                                                                             
                                                                                                                                                                                          
  6                      19               0211                  African-American   9 2/7             None                    No                Yes                          0             No
                                                                                                                                                                                          
  7                      29               1021                  African-American   7 2/7             Laparotomy                                No                           0             No
  (trauma),              Yes                                                                                                                                                              
  appendectomy,          (cocaine,                                                                                                                                                        
  pneumonia,             alcohol,                                                                                                                                                         
  Hepatitis C, history   tobacco)                                                                                                                                                         
  of syphilis                                                                                                                                                                             
  ---------------------- ---------------- --------------------- ------------------ ----------------- ----------------------- ----------------- ---------------------------- ------------- ------

###### 

HIV and infectious morbidity. HIV: human immunodeficiency virus; AIDS: acquired immunodeficiency syndrome; HAART: highly active antiretroviral therapy; AZT: zidovudine; INH: isoniazide; PACTG: the Pediatric AIDS Clinical Trials Group; TB: tuberculosis; S/P: status-post.

  ----------------- ---------------------- -------------------------------- ------------------------------- ------------- -------------------- --------------- -------------------- ---------------
  Patient           Prepregnancy therapy   Initial viral load (copies/mL)   Initial CD4 count (abs/mm^3^)   Gestational   Antepartum therapy   Vaginal         Viral coinfections   PPD status
  age at            infections                                                                                                                                                      
  initiations       in this                                                                                                                                                         
  of HAART          pregnancy                                                                                                                                                       
                                                                                                                                                                                    
  1                 None                   2672                             508                             None          AZT                  *Trichomonas*   None                 Negative
  *C trachomatis*                                                                                                                                                                   
  *Gonorrhea*                                                                                                                                                                       
                                                                                                                                                                                    
  2                 None                   179                              858                             15 0/7        Combivir             None            None                 Negative
  Neviripine                                                                                                                                                                        
                                                                                                                                                                                    
  3                 Neviripine             \< 50                            684                             15 3/7        Neviripine           None            Hepatitis A          Positive, s/p
  Lamivudine        Lamivudine             INH                                                                                                                                      
  Stavudine         Stavudine              prophylaxis                                                                                                                              
                                                                                                                                                                                    
  4                 Combivir               \< 50                            407                             13 0/7        Combivir             None            None                 Negative
  Neviripine                                                                                                                                                                        
                                                                                                                                                                                    
  5                 None                   971                              312                             14 0/7        Combivir             *Trichomonas*   None                 Negative
                                                                                                                                                                                    
  6                 None                   N/A                              766                             None          (Placebo             None            None                 Negative
  arm of                                                                                                                                                                            
  PACTG                                                                                                                                                                             
  076\)                                                                                                                                                                             
                                                                                                                                                                                    
  7                 AZT                    N/A                              N/A                             None          AZT                  *Trichomonas*   Hepatitis C          h/o TB, s/p
  therapy                                                                                                                                                                           
  ----------------- ---------------------- -------------------------------- ------------------------------- ------------- -------------------- --------------- -------------------- ---------------

###### 

PPROM and delivery characteristics. PPROM: preterm premature rupture of membranes; HAART: highly active antiretroviral therapy; AZT: zidovudine; C/S: cesarean delivery; IUFD: intrauterine fetal demise; NSVD: spontaneous vaginal delivery; N/A: data not available.

  ----------------- ------------- --------------- ------------- --------------------------------- ----------------------- --------------------- ------------- --------------- ----------------------------------- ------------------ ---------- ------------ ----------------------
  Patient           Gestational   Viral load at   CD4 count     HAART at PPROM                    Intrapartum             Latency antibiotics   Interval to   Viral load at   Indication for delivery             Mode of delivery   Clinical   Histologic   Histologic funisitis
  age at            PPROM         at PPROM        AZT therapy   delivery                          delivery                chorio                chorio                                                                                                       
  PPROM             (copies/mL)   (abs/mm^3^)     (days)        (days)                            (copies/mL)             amnionitis            amnionits                                                                                                    
                                                                                                                                                                                                                                                             
  1                 30 5/7        1809            508           Combivir                          Yes                     No                    1             1809            Labor prior classical               C/S                No         No           No
  (2 hours)                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                             
  2                 17 2/7        7319            724           None                              None                    No                    92            179             IUFD                                SVD                No         Unknown      Unknown
  indicated                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                             
  3                 30 2/7        \< 50           684           Neviripine Lamivudine Stavudine   No (adverse reaction)   Yes                   5             \< 50           Chorio nonreassuring fetal status   C/S                Yes        Yes          Yes
                                                                                                                                                                                                                                                             
  4                 31 4/7        \< 50           407           Combivir                          Yes                     Yes                   2             \< 50           Chorio                              SVD                Yes        Yes          Yes
  Neviripine        (2 days)                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                             
  5                 24 2/7        3710            312           Combivir                          Yes                     No                    10            971             Labor                               C/S                No         Yes          Yes
  AZT (2 days);     nonreassur-                                                                                                                                                                                                                              
  HAART (8 days);   ing fetal                                                                                                                                                                                                                                
  AZT (4 hours)     status                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                             
  6                 31 0/7        N/A             459           None                              None                    Yes                   3             N/A             Chorio                              SVD                Yes        N/A          N/A
                                                                                                                                                                                                                                                             
  7                 23 4/7        N/A             N/A           None                              Yes                     Yes                   7             N/A             Labor                               SVD                No         N/A          N/A
  (3 days)                                                                                                                                                                                                                                                   
  ----------------- ------------- --------------- ------------- --------------------------------- ----------------------- --------------------- ------------- --------------- ----------------------------------- ------------------ ---------- ------------ ----------------------

###### 

Infant sequelae and complications. N/A: not assessable, secondary to intrauterine fetal death. NICU: neonatal intensive care unit; RDS: respiratory distress syndrome; IVH: intraventricular hemorrhage; NEC: necrotizing enterocolitis; IUFD: intrauterine fetal demise; VSD: ventriculoseptal defect.

  --------------------- ----------- --------------- ------------------ ---------------- ------ -------------------- ------------------------ -----------------------
  Patient               Delivery    Infant gender   Birth weight (g)   Apgars (1,5 m)   NICU   Antenatal steroids   Neonatal complications   Vertical transmission
  gestational           admission                                                                                                            
  age (weeks)           (days)                                                                                                               
                                                                                                                                             
  1                     31 5/7      Male            1660               6, 9             29     Yes                  RDS                      No
                                                                                                                                             
  2                     30 2/7      Female          710                0, 0             IUFD   Yes                  IUFD                     N/A
                                                                                                                                             
  3                     31 0/7      Male            1360               6, 7             53     Yes                  None                     No
                                                                                                                                             
  4                     31 6/7      Female          2000               9, 9             7      Yes                  None                     No
                                                                                                                                             
  5                     25 5/7      Male            778                3, 3             148    Yes                  RDS, pyloric             No
  stenosis, VSD                                                                                                                              
  retinopathy of                                                                                                                             
  prematurity,                                                                                                                               
  fetal alcohol                                                                                                                              
  syndrome                                                                                                                                   
                                                                                                                                             
  6                     31 3/7      Male            1605               5, 8             29     No                   RDS,                     Yes
  neutropenia                                                                                                                                
                                                                                                                                             
  7                     24 4/7      Male            827                1, 7             60     No                   RDS,                     Yes
  IVH grade 1, anemia                                                                                                                        
  --------------------- ----------- --------------- ------------------ ---------------- ------ -------------------- ------------------------ -----------------------
